Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe

About this update from Crescita Therapeutics, Inc.

[{"type":"text","content":"\n \n \n \n Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VIENNA\n \n \n ,\n \n \n June 1, 2023\n \n \n /CNW/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis\n \n ®\n \n , a topical local anaesthetic for superficial dermatological procedures, in its European core markets including\n \n Germany\n \n , the\n \n United Kingdom\n \n (\"UK\"), and\n \n Ireland\n \n . Further markets including\n \n Brazil\n \n will follow by the end of 2023. The anaesthetic cream complements Croma's range of aesthetic injectables, a key pillar of its comprehensive and innovative aesthetics portfolio.\n \n \n \n \n \n The launch is preceded by an exclusive licensing agreement for Pliaglis\n \n ®\n \n with Canadian dermatology company Crescita Therapeutics Inc. (\"Crescita\"). The agreement grants Croma the exclusive rights to commercialize Pliaglis in nine countries including\n \n Germany\n \n ,\n \n Ireland\n \n ,\n \n Switzerland\n \n ,\n \n Belgium\n \n ,\n \n Luxembourg\n \n , the UK and\n \n Netherlands\n \n and\n \n Brazil\n \n .\n \n \n \"Pliaglis perfectly complements our range of aesthetic injectables. It is a further essential building block in our focused and differentiated aesthetics portfolio and proof of our full dedication to medical aesthetics. The planned launch of Pliaglis in our European markets and in\n \n Brazil\n \n in 2023 will further accelerate our growth,\" commented\n \n Andreas Prinz\n \n , CEO. \"We are thrilled about our partnership with Crescita, together bringing this therapeutic option to healthcare professionals in our core markets.\"\n \n \n Specifically designed and licensed for anaesthetic needs in aesthetic medicine, Pliaglis\n \n ®\n \n is applied by the medical professional before a wide range of minimally invasive aesthetic procedures such as dermal filler or laser treatments, to provide effective and long-lasting local...

More updates from Crescita Therapeutics, Inc.